Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.

mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes. Clin Cancer Res; 22(14); 3419-21. ©2016 AACRSee related article by Vallera et al., p. 3440. ©2016 American Association for Cancer Research.